Compare CCHH & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCHH | XAIR |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2M | 10.5M |
| IPO Year | 2025 | N/A |
| Metric | CCHH | XAIR |
|---|---|---|
| Price | $0.51 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 2.0M | 138.8K |
| Earning Date | 02-08-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $9,138,264.00 | $5,802,000.00 |
| Revenue This Year | N/A | $128.45 |
| Revenue Next Year | N/A | $153.25 |
| P/E Ratio | $40.58 | ★ N/A |
| Revenue Growth | N/A | ★ 147.74 |
| 52 Week Low | $0.49 | $0.67 |
| 52 Week High | $15.39 | $10.40 |
| Indicator | CCHH | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 23.80 |
| Support Level | N/A | $0.67 |
| Resistance Level | N/A | $1.31 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 11.98 |
CCH Holdings Ltd operates a hotpot restaurant chain in Malaysia, specializing in chicken hotpot and fish head hotpot, mainly under two brand, namely Chicken Claypot House and Zi Wei Yuan, owned by the wholly owned subsidiaries of the Company. The Company conducts its operations through its wholly owned subsidiaries in Malaysia and is engaged as a restaurant operator, licensor and loyalty owner, and general trader. Currently, the Group has developed a restaurant chain including approximately 15 company-owned restaurant outlets, 13 franchised restaurant outlets in Malaysia, and 4 franchised restaurant outlets outside Malaysia.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.